Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Japanese pediatric patients with pulmonary arterial hypertension
jRCT2011210057Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Janssen Pharmaceutical. Primary endpoint: Fold change in pulmonary vascular resistance index (PVRI) at Week 24. Started Dec 2022; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2011210057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210057.